

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Nancy E. Yorke  
Name

Nancy E. Yorke  
Signature

June 21, 2005  
Date



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lowe, et al.

Serial No.: 09/762,794 - Case No.: 20276P

Art Unit: 1636

Filed: March 23, 2001

Examiner: Guzo

For: PROTEIN DELIVERY SYSTEM USING HUMAN  
PAPILLOMAVIRUS VIRUS-LIKE PARTICLES

The Honorable Commissioner of Patents and Trademarks  
P.O. Box 1415  
Alexandria, VA 22313-1450

COMMUNICATION

Sir:

This communication is in response to the Notice of Allowability and Examiner's Amendment/Comment, mailed March 21, 2005 for the above-referenced case. We note that the issue fee and response to the Examiner's comment is due by June 21, 2005.

The Examiner's Comment, appearing on page 2 of the Notice of Allowability, states that a substitute oath or declaration must be submitted because the filing date listed on the declaration for PCT/US99/17931 should state August 10, 1999 rather than the listed date of August 14, 1999. In response thereto, Applicants have prepared and enclose herewith a signed, substitute declaration, as requested by the Examiner.

In accordance with the obligation under 37 C.F.R. § 1.56, Applicants bring to the attention of the Examiner the following published references, cited by the European Patent Office in the equivalent European application:

Sun et al. *Virology* 213: 321-27 (1995)

Zhou et al. *Journal of Virology* 68: 619-25 (1994)

Duggan-Keen et al. *Frontiers in Bioscience* 3: 1192-1208 (1998)

The information disclosure statement and references, transmitted herewith are being filed after a Notice of Allowance under § 1.311, but concurrently with the payment of the issue fee.


The references and the information disclosure statement transmitted herewith are submitted under 37 CFR § 1.97 (i). Under § 1.97 (i), information disclosure statements, filed before the grant of a patent will be placed in the file, but will not be considered by the Office.

The Information Disclosure Statement is not an admission that the information provided above is material to patentability in accordance with 37 C.F.R. § 1.97(h).

Applicants respectfully request that this information disclosure statement and corresponding references be placed in the file of the instant application.

It is believed that a fee is not due for this submission. However, if such a fee is due in connection with this submission, please charge deposit account 13-2755.

Respectfully submitted,


By   
Alysia A. Finnegan  
Reg. No. 48,878  
Attorney for Applicant

MERCK & CO., INC.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-2583

Date: June 21, 2005

B1 & FW 1636

<b>MISC. FEE TRANSMITTAL</b>		<i>Complete if Known</i>	
<p>Patent fees are subject to annual revision.</p> <p><b>TOTAL AMOUNT OF PAYMENT</b> \$130</p>		<b>Application Number</b>	09/762,794
		<b>Filing Date</b>	March 23, 2001
		<b>First Named Inventor</b>	Lowe, et al.
		<b>Examiner Name</b>	Guzo
		<b>Group Art Unit</b>	1636
		<b>Attorney Docket Number</b>	20276P



<b>METHOD OF PAYMENT</b>	
<input checked="" type="checkbox"/> Deposit Account	
Deposit Account Number	13-2755
Deposit Account Name	Merck & Co., Inc.
The Director is authorized to:	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input checked="" type="checkbox"/> Credit any overpayments
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17	

<b>FEE CALCULATION</b>				
FEES	Fee Code	Fee (\$)	Fee Description	Fee Paid
Large Entity	1051	130	Surcharge - late filing fee or oath	130
	1051	130	Non-English Specification	
	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
	1402	500	Filing a brief in support of an appeal	
	1452	500	Petition to revive - unavoidable	
	1453	1,500	Petition to revive - unintentional	
	1807	50	Processing fee under 37 CFR 1.17(q)	
	1806	180	Submission of Information Disclosure Statement	
	1809	790	Filing a submission after final rejection (37 CFR 1.129(a))	
	1810	790	For each additional invention to be examined (37 CFR 1.129(b))	
			Other fee (specify) _____	
			Other fee (specify) _____	
<b>TOTAL</b>				\$130

<b>SUBMITTED BY</b>			<b>Complete (if applicable)</b>	
Typed or Printed Name	Alysia A. Finnegan		Reg. Number	48,878
Signature		Date	06/21/2005	Deposit Account User ID

06/24/2005 CCHAU1 00000047 132755 09762794  
01 FC:1051 130.00 DA

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

By Merck & Co., Inc. Date June 21, 2005